NASDAQ:PTLAPortola Pharmaceuticals Stock Price, Forecast & News

$17.85

-0.04 (-0.22 %)

(As of 05/28/2020 04:00 PM ET)

Add

Compare

Today's Range

$17.84

Now: $17.85▼

$17.88

50-Day Range

$6.41

MA: $11.78▼

$17.90

52-Week Range

$5.31

Now: $17.85▼

$31.73

Volume1.91 million shs

Average Volume3.39 million shs

Market Capitalization$1.40 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.76

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.

Beat the Market (BTM) Rank^™

3.1 Analyst's Opinion

Consensus Rating
Portola Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $29.14, Portola Pharmaceuticals has a potential upside of 63.3% from its current price of $17.85.
Amount of Analyst Coverage
Portola Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
Portola Pharmaceuticals has received 513 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Portola Pharmaceuticals has received 360 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Portola Pharmaceuticals has received 58.76% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote “Outperform” if you believe PTLA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PTLA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Portola Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Portola Pharmaceuticals does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Portola Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.50% of the stock of Portola Pharmaceuticals is held by insiders.
Percentage Held by Institutions
98.68% of the stock of Portola Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Portola Pharmaceuticals are expected to grow in the coming year, from ($2.88) to ($2.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Portola Pharmaceuticals is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Portola Pharmaceuticals is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Portola Pharmaceuticals has a P/B Ratio of 19.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.53 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:PTLA

Previous Symbol

CUSIPN/A

CIK1269021

Webwww.portola.com

Phone650-246-7000

Debt

Debt-to-Equity Ratio4.77

Current Ratio4.87

Quick Ratio4.82

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$116.64 million

Price / Sales12.01

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.92 per share

Price / Book19.40

Profitability

EPS (Most Recent Fiscal Year)($4.06)

Net Income$-290,660,000.00

Net Margins-232.73%

Return on Equity-267.86%

Return on Assets-54.66%

Miscellaneous

Employees324

Outstanding Shares78,484,000

Market Cap$1.40 billion

Next Earnings Date8/5/2020 (Estimated)

OptionableOptionable

Receive PTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for PTLA and its competitors with MarketBeat's FREE daily newsletter.

Portola Pharmaceuticals (NASDAQ:PTLA) Frequently Asked Questions

How has Portola Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Portola Pharmaceuticals' stock was trading at $8.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PTLA stock has increased by 109.0% and is now trading at $17.85. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Portola Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Portola Pharmaceuticals in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Portola Pharmaceuticals.

When is Portola Pharmaceuticals' next earnings date?

Portola Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Portola Pharmaceuticals.

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals Inc (NASDAQ:PTLA) issued its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.88) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.74) by $0.14. The biopharmaceutical company had revenue of $26.40 million for the quarter, compared to analysts' expectations of $33.88 million. Portola Pharmaceuticals had a negative net margin of 232.73% and a negative return on equity of 267.86%. The business's revenue was up 18.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.02) earnings per share. View Portola Pharmaceuticals' earnings history.

What price target have analysts set for PTLA?

8 brokerages have issued 12-month price targets for Portola Pharmaceuticals' stock. Their forecasts range from $17.00 to $44.00. On average, they anticipate Portola Pharmaceuticals' share price to reach $29.14 in the next year. This suggests a possible upside of 63.3% from the stock's current price. View analysts' price targets for Portola Pharmaceuticals.

Has Portola Pharmaceuticals been receiving favorable news coverage?

News articles about PTLA stock have trended extremely positive this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Portola Pharmaceuticals earned a news sentiment score of 4.7 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future. View the latest news aboutPortola Pharmaceuticals.

Who are some of Portola Pharmaceuticals' key competitors?

Some companies that are related to Portola Pharmaceuticals include United Therapeutics (UTHR), Myokardia (MYOK), Reata Pharmaceuticals (RETA), Forty Seven (FTSV), Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), PPD (SDGR), Global Blood Therapeutics (GBT), GW Pharmaceuticals PLC- (GWPH), Nektar Therapeutics (NKTR), Zai Lab (ZLAB), Evotec (EVTCY) and ChemoCentryx (CCXI). View all competitors.

What other stocks do shareholders of Portola Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Portola Pharmaceuticals investors own include Lexicon Pharmaceuticals (LXRX), Novavax (NVAX), Iovance Biotherapeutics (IOVA), Editas Medicine (EDIT), Exelixis (EXEL), Amarin (AMRN), Geron (GERN), NVIDIA (NVDA), Inovio Pharmaceuticals (INO) and Aileron Therapeutics (ALRN).

Who are Portola Pharmaceuticals' key executives?

Portola Pharmaceuticals' management team includes the following people:

Ms. Mardi C. Dier, Exec. VP, Chief Bus. Officer & CFO (Age 55)
Dr. John T. Curnutte, Exec. VP and Head of R&D (Age 67)
Mr. J. Scott Garland M.B.A., MBA, Pres & CEO (Age 50)
Cara Miller, VP of Investor Relations and Corp. Communications
Mr. John B. Moriarty Jr., Exec. VP, Gen. Counsel & Sec. (Age 51)

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

Who are Portola Pharmaceuticals' major shareholders?

Portola Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (13.67%), William Blair Investment Management LLC (12.74%), BlackRock Inc. (7.76%), State Street Corp (4.13%), Rock Springs Capital Management LP (2.23%) and Fiera Capital Corp (2.17%). Company insiders that own Portola Pharmaceuticals stock include Charles J Homcy, Hollings Renton, Jeffrey W Bird, Mardi Dier and William Lis. View institutional ownership trends for Portola Pharmaceuticals.

Which major investors are selling Portola Pharmaceuticals stock?

PTLA stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, Pictet Asset Management Ltd., BlackRock Inc., Rafferty Asset Management LLC, Tekla Capital Management LLC, Fiera Capital Corp, Blair William & Co. IL, and Pinnacle Associates Ltd.. View insider buying and selling activity for Portola Pharmaceuticals.

Which major investors are buying Portola Pharmaceuticals stock?

PTLA stock was purchased by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Rock Springs Capital Management LP, Morgan Stanley, Morgan Stanley, Deutsche Bank AG, Two Sigma Advisers LP, Two Sigma Investments LP, and Wellington Management Group LLP. View insider buying and selling activity for Portola Pharmaceuticals.

How do I buy shares of Portola Pharmaceuticals?

Shares of PTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Portola Pharmaceuticals' stock price today?

One share of PTLA stock can currently be purchased for approximately $17.85.

How big of a company is Portola Pharmaceuticals?

Portola Pharmaceuticals has a market capitalization of $1.40 billion and generates $116.64 million in revenue each year. The biopharmaceutical company earns $-290,660,000.00 in net income (profit) each year or ($4.06) on an earnings per share basis. Portola Pharmaceuticals employs 324 workers across the globe.

What is Portola Pharmaceuticals' official website?

The official website for Portola Pharmaceuticals is www.portola.com.

How can I contact Portola Pharmaceuticals?

Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff